In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

M illions of Americans have tried GLP-1 medications like Ozempic, Mounjaro and Wegovy, polls show, but pharmacy claims data ...

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.